Oramed Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Oramed Pharmaceuticals CEO'su Nadav Kidron, Mar2006 tarihinde atandı, in görev süresi 18.92 yıldır. in toplam yıllık tazminatı $ 1.66M olup, şirket hissesi ve opsiyonları dahil olmak üzere 27.9% maaş ve 72.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.32% ine doğrudan sahiptir ve bu hisseler € 2.90M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 12.2 yıl ve 8.4 yıldır.

Anahtar bilgiler

Nadav Kidron

İcra Kurulu Başkanı

US$1.7m

Toplam tazminat

CEO maaş yüzdesi	27.9%
CEO görev süresi	18.9yrs
CEO sahipliği	3.3%
Yönetim ortalama görev süresi	12.2yrs
Yönetim Kurulu ortalama görev süresi	8.4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Nadav Kidron'un ücretlendirmesi Oramed Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$4m
Jun 30 2024	n/a	n/a	US$21m
Mar 31 2024	n/a	n/a	US$10m
Dec 31 2023	US$2m	US$463k	US$6m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$30m
Dec 31 2022	US$7m	US$491k	-US$37m
Sep 30 2022	n/a	n/a	-US$46m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	n/a	n/a	-US$35m
Nov 30 2021	n/a	n/a	-US$25m
Aug 31 2021	US$4m	US$466k	-US$22m
May 31 2021	n/a	n/a	-US$18m
Feb 28 2021	n/a	n/a	-US$15m
Dec 31 2020	n/a	n/a	-US$22m
Nov 30 2020	n/a	n/a	-US$15m
Aug 31 2020	US$2m	US$439k	-US$12m
May 31 2020	n/a	n/a	-US$11m
Feb 29 2020	n/a	n/a	-US$13m
Nov 30 2019	n/a	n/a	-US$13m
Aug 31 2019	US$2m	US$419k	-US$14m
May 31 2019	n/a	n/a	-US$15m
Feb 28 2019	n/a	n/a	-US$15m
Nov 30 2018	n/a	n/a	-US$14m
Aug 31 2018	US$2m	US$436k	-US$13m

Tazminat ve Piyasa: Nadav 'nin toplam tazminatı ($USD 1.66M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 456.62K ).

Tazminat ve Kazançlar: Nadav 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Nadav Kidron (50 yo)

18.9yrs

Görev süresi

US$1,659,222

Tazminat

Mr. Nadav Kidron, Esq. has been the Chief Executive Officer and President of Oramed Pharmaceuticals Inc. (Alternatively Integrated Security Technologies Inc) since March 08, 2006. Mr. Kidron served as an i...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nadav Kidron	President	18.9yrs	US$1.66m	3.32% € 2.9m
Miriam Kidron	Chief Scientific Officer & Director	18.9yrs	US$1.11m	1.16% € 1.0m
Avraham Gabay	CFO, Treasurer & Secretary	less than a year	US$1.05m	0.074% € 64.8k
Joshua Hexter	Chief Operating & Business Officer	5.4yrs	US$1.28m	0.81% € 707.2k

12.2yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: OJU1 'un yönetim ekibi deneyimli ve deneyimlidir ( 12.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nadav Kidron	President	18.9yrs	US$1.66m	3.32% € 2.9m
Miriam Kidron	Chief Scientific Officer & Director	18.9yrs	US$1.11m	1.16% € 1.0m
Jay Skyler	Member of Scientific Advisory Board	5.1yrs	Veri yok	Veri yok
Eleuterio Ferrannini	Member of Scientific Advisory Board	18yrs	Veri yok	Veri yok
Harold Jacob	Member of Scientific Advisory Board	8.3yrs	US$20.00k	Veri yok
Avram Hershko	Member of Scientific Advisory Board	16.6yrs	Veri yok	Veri yok
G. Alexander Fleming	Member of Scientific Advisory Board	5.2yrs	Veri yok	Veri yok
Leonard Sank	Independent Director	17.3yrs	US$112.28k	0.081% € 70.3k
Roy Eldor	Member of the Scientific Advisory Board	8.6yrs	Veri yok	Veri yok
Anne Peters	Member of Scientific Advisory Board	2.7yrs	Veri yok	Veri yok
Arie Mayer	Independent Director	5.2yrs	US$127.28k	0.076% € 66.2k
Julio Rosenstock	Member of Scientific Advisory Board	5.1yrs	Veri yok	Veri yok

8.4yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OJU1 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/02 16:48
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Oramed Pharmaceuticals Inc. 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andrew D'Silva	B. Riley Securities, Inc.
Edward Nash	Canaccord Genuity
Charles Duncan	Cantor Fitzgerald & Co.

Oramed Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Recent updates

New major risk - Earnings quality

Investor sentiment deteriorates as stock falls 15%

New minor risk - Market cap size

Investor sentiment improves as stock rises 22%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: EPS: US$0.14 (vs US$0.94 loss in FY 2022)

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New major risk - Share price stability

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.03 loss per share (vs US$0.27 loss in 2Q 2022)

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

First quarter 2023 earnings released: US$0.085 loss per share (vs US$0.27 loss in 1Q 2022)

President recently bought €188k worth of stock

Independent Director recently bought €132k worth of stock

Full year 2022 earnings released: US$0.94 loss per share (vs US$0.94 loss in FY 2021)

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.21 loss in 3Q 2021)

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 2Q 2021)

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.17 loss in 1Q 2021)

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings released: US$0.94 loss per share (vs US$0.90 loss in FY 2020)

Independent Chairman of the Board recently sold €85k worth of stock

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Independent Chairman of the Board recently sold €376k worth of stock

Independent Director Xiaoming Gao has left the company

Oramed Pharmaceuticals Inc. Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

Oramed Pharmaceuticals Inc. Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.098 loss in 3Q 2020)

CFO, Treasurer & Secretary Avraham Gabay has left the company

Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2020)

Oramed Pharmaceuticals Inc. Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

New 90-day high: €9.23

New 90-day high: €5.31

Oramed Pharmaceuticals Inc. Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study

Revenue beats expectations

Revenue beats expectations

First quarter 2021 earnings released: US$0.23 loss per share

Oramed Pharmaceuticals Inc. Reports Positive First in Human Data from Oral Leptin Study

Oramed Pharmaceuticals Inc. Initiates Phase 2 NASH Trial of Oral Insulin

New 90-day high: €3.34

Revenue misses expectations

Oramed Pharmaceuticals Inc Initiates Phase 3 Trial of Oral Insulin

Full year 2020 earnings released: US$0.56 loss per share